Standard & Poor’s has affirmed its ‘A-‘ counterparty credit and financial strength ratings and negative outlook on Amedex Insurance Co.
Standard & Poor’s subsequently withdrew the ratings at the company’s request. The ratings reflected Amedex’s good business position as a niche provider of major medical products in Latin America, favorable operating performance, and strong capitalization.
These positive factors are offset by Amedex’s limited size, declining enrollment trends, new business risk through Amedex Bermuda, and high operating expenses, which are the direct consequence of its target market and high level of service provided.
Was this article valuable?
Here are more articles you may enjoy.
Berkshire Utility Presses Wildfire Appeal With Billions at Stake
Portugal Rolls Out $2.9 Billion Aid as Deadly Flooding Spreads
US Will Test Infant Formula to See If Botulism Is Wider Risk
Navigators Can’t Parse ‘Additional Insured’ Policy Wording in Georgia Explosion Case